A PHASE 3, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY OF XALURITAMIG PLUS ABIRATERONE VERSUS INVESTIGATOR’S CHOICE IN PARTICIPANTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- Registry ID
- 20230239
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- AMGEN CANADA INC
- Start date
- 2026-04-02
- Last update
- 2026-03-05
Conditions
- PROSTATE CANCER METASTATIC CASTRATION RESISTANT
Related clinical trials
- A PHASE III, MULTICENTRE, RANDOMISED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD2265 (FPI-2265) 225AC-PSMA-I&T COMPARED WITH STANDARD OF CARE IN PATIENTS WITH PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (VECTRA-01)
- A PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF PASRITAMIG (JNJ-78278343), A T-CELL-REDIRECTING AGENT TARGETING HUMAN KALLIKREIN 2, WITH DOCETAXEL VERSUS DOCETAXEL FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF
PASRITAMIG (JNJ-78278343), A T-CELL-REDIRECTING AGENT TARGETING
HUMAN KALLIKREIN 2, + BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE
CARE FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- A PHASE 1/2 PLATFORM
STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IFINATAMAB DERUXTECAN AS
MONOTHERAPY OR IN COMBINATION WITH OTHER TREATMENTS IN PARTICIPANTS
WITH PROSTATE CANCER
- A PHASE 1 OPEN-LABEL, FIRST-IN-HUMAN, MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF ACTINIUM-225-MACROPA-PELGIFATAMAB (BAY 3546828) IN PARTICIPANTS WITH ADVANCED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
- A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF OPEVESOSTAT VERSUS ALTERNATIVE ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATIONRESISTANT PROSTATE CANCER (MCRPC) THAT PROGRESSED ON OR AFTER PRIOR TREATMENT WITH ONE NEXT- GENERATION HORMONAL AGENT (NHA) (OMAHA-004)
View on source registry